"Merck on Thursday announced that its blockbuster PD-1 inhibitor Keytruda (pembrolizumab) fell short of its dual primary endpoints in the Phase III KEYLYNK-006 trial, unable to significantly improve survival outcomes in specific patients with metastatic non-squamous non-small cell lung cancer." the article says.
https://www.biospace.com/article/merck-s-keytruda-continues-losing-streak-in-nsclc-with-phase-iii-flop/?utm_campaign=Daily%20Social%20%7C%20News&utm_content=286824601&utm_medium=social&utm_source=linkedin&hss_channel=lcp-424124
bisantrene could be Keytruda's saviour...
- Forums
- ASX - By Stock
- Industry news
"Merck on Thursday announced that its blockbuster PD-1 inhibitor...
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.32 |
Change
0.055(4.37%) |
Mkt cap ! $218.5M |
Open | High | Low | Value | Volume |
$1.26 | $1.33 | $1.26 | $149.9K | 115.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 400 | $1.27 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.35 | 1000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 400 | 1.265 |
2 | 3000 | 1.260 |
2 | 26300 | 1.255 |
3 | 20926 | 1.250 |
1 | 1000 | 1.220 |
Price($) | Vol. | No. |
---|---|---|
1.350 | 1000 | 1 |
1.380 | 3000 | 1 |
1.390 | 8179 | 2 |
1.400 | 8530 | 3 |
1.430 | 12075 | 1 |
Last trade - 16.10pm 09/05/2024 (20 minute delay) ? |
|
|||||
Last
$1.29 |
  |
Change
0.055 ( 4.34 %) |
|||
Open | High | Low | Volume | ||
$1.26 | $1.33 | $1.26 | 12903 | ||
Last updated 15.43pm 09/05/2024 ? |
Featured News
RAC (ASX) Chart |